1.上海中医药大学(上海 201203)
2.四川省药品检验研究院,四川省医疗器械检测中心(四川 成都 611731)
3.国家药品监督管理局药物制剂体内外相关性技术研究重点实验室(四川 成都 611731)
徐嘉若,女,在读硕士生,主要从事中药新药及药理学研究
陈佳靓,工程师;E-mail:409786396@qq.com
姚广涛,副研究员,硕士生导师; E-mail:yaoguangyao1969@126.com
纸质出版日期:2024-03-25,
收稿日期:2023-07-02,
修回日期:2023-09-19,
扫 描 看 全 文
徐嘉若,贾丰菁,陈佳靓等.双氢青蒿素通过调控MAPK/PI3K/Akt信号通路抗结直肠癌作用研究[J].上海中医药大学学报,2024,38(02):83-92.
XU Jiaruo,JIA Fengjing,CHEN Jialiang,et al.Research of dihydroartemisinin on anti‑colorectal cancer by regulating MAPK/PI3K/Akt signaling pathway[J].Academic Journal of Shanghai University of Traditional Chinese Medicine,2024,38(02):83-92.
徐嘉若,贾丰菁,陈佳靓等.双氢青蒿素通过调控MAPK/PI3K/Akt信号通路抗结直肠癌作用研究[J].上海中医药大学学报,2024,38(02):83-92. DOI: 10.16306/j.1008-861x.2024.02.012.
XU Jiaruo,JIA Fengjing,CHEN Jialiang,et al.Research of dihydroartemisinin on anti‑colorectal cancer by regulating MAPK/PI3K/Akt signaling pathway[J].Academic Journal of Shanghai University of Traditional Chinese Medicine,2024,38(02):83-92. DOI: 10.16306/j.1008-861x.2024.02.012.
目的
2
探讨双氢青蒿素(DHA)在体内对人结直肠癌(RKO)细胞的抗癌活性及体外机制。
方法
2
将40只SPF级雄性裸鼠建立RKO荷瘤小鼠模型,随机分为模型组、顺铂组及DHA高剂量(200 mg/kg)、低剂量(100 mg/kg)组,每组10只;对比各组裸鼠体质量、肿瘤体积、肿瘤质量、抑瘤率、血清肿瘤坏死因子(TNF-α)水平等;苏木素-伊红(HE)染色观察各组裸鼠肿瘤组织病理学变化;噻唑蓝(MTT)比色法检测不同浓度(25、50、100 μmol/L)DHA干预0、24、48、72 h内对RKO细胞增殖的影响;流式细胞仪、Hoechst 33258检测(0、50、95、150 μmol/L)DHA干预48 h后对RKO细胞周期和细胞凋亡的影响;划痕实验观察95 μmol/L DHA干预对细胞迁移能力的影响;实时荧光定量PCR(RT-qPCR)检测DHA对细胞内半胱氨酸天冬氨酸蛋白酶-3(
Caspase
-
3
)、
Caspase
-
9
、B细胞淋巴瘤-2(
Bcl
-
2
)、Bcl-2相关X蛋白(
Bax
) mRNA表达水平的影响;蛋白质印迹法(Western blot)检测DHA对细胞内Caspase-3、Caspase-9、Bcl-2、Bax以及p38-丝裂原活化蛋白激酶(p38-MAPK)、p-p38-MAPK、磷脂酰肌醇3-激酶(PI3K)、p-PI3K、蛋白激酶B(Akt)、p-Akt、基质金属蛋白酶(MMP-9)等表达水平的影响。
结果
2
200 mg/kg DHA显著降低肿瘤体积和质量,降低血清TNF-α水平,抑瘤率为41.45%;DHA可随浓度的增加而增强对RKO细胞增殖的抑制作用;(50、95、150 μmol/L)DHA阻滞RKO细胞周期在G
2
/M期,且促进RKO细胞凋亡作用随DHA浓度增加而增强; 95 μmol/L DHA干预12、24 h后可显著降低RKO细胞迁移能力(
P
<
0.01);95 μmol/L DHA可显著上调RKO细胞内
Caspase
-
3
、
Caspase
-
9
mRNA表达水平(
P
<
0.01)以及
Bax
/
Bcl
-
2
mRNA表达比值(
P
<
0.05);95 μmol/L DHA可增加RKO细胞内剪切型Caspase-9(cleaved-Caspase-9)/Caspase-9、Bax/Bcl-2蛋白表达(
P
<
0.01),同时降低MMP-9、p-P38 MAPK、p-PI3K、p-Akt及Akt蛋白表达水平(
P
<
0.01)。
结论
2
DHA有较好的抑制结直肠癌作用,其机制可能为抑制MAPK/PI3K/Akt信号通路,触发RKO细胞内源性凋亡,阻止其增殖与迁移。
Objective: To investigate the anticancer activity of dihydroartemisinin(DHA)on RKO cells
in vivo
and its mechanism
in vitro
.
Methods
2
40 RKO tumor-bearing mouse models were established in specific pathogen-free male nude mice and randomly divided into model group,cisplatin group,high dose DHA(200 mg/kg)group,and low dose DHA(100 mg/kg)group,with 10 mice in each group. The body weight,tumor volume,tumor mass,tumor inhibition rate and serum,tumor necrosis factor-α(TNF-α)level of each group were compared. Hematoxylin-eosin (H
&
E) staining was used to observe tumor histopathological changes in nude mice of each group. MTT assay was used to detect the effects of DHA at different concentrations(25,50,100 μmol/L)on the proliferation of RKO cells within 0,24,48,and 72 h. Flow cytometry and Hoechst 33258 were used to detect the effects of DHA (0,50,95,150 μmol/L)on the cell cycle and apoptosis of RKO cells after 48 h intervention. Wound healing assay was used to observe the effect of 95 μmol/L DHA on cell migration. Real Time Quantitative PCR (RT-qPCR) was used to detect the effect of DHA on the mRNA expression levels of
Caspase
-
3
,
Caspase
-
9
,
Bcl
-
2
and
Bax
. Western blot was used to detect the effect of DHA on the expression levels of Caspase-3, Caspase-9, Bcl-2, Bax, p38-MAPK, p-p38-MAPK, PI3K, p-PI3K, Akt, p-Akt and MMP-9.
Results
2
Tumor volume and mass were significantly reduced and the serum level of TNF-α was lowered by 200 mg/kg DHA, and the tumor inhibition rate was 41.45%. The inhibitory effect on RKO cell proliferation was enhanced with increasing concentration of DHA. RKO cell cycle was arrested in the G2/M phase by (50,95,150 μmol/L)DHA,and the effect of promoting RKO cell apoptosis was enhanced with the increase of DHA concentration. The migration ability of RKO cells was significantly reduced after intervention with 95 μmol/L DHA for 12 and 24 h (
P
<
0.01). The mRNA expression levels of
Caspase
-
3
and
Caspase
-
9
in RKO cells were significantly up-regulated by 95 μmol/L DHA(
P
<
0.01), and
Bax
/
Bcl
-
2
mRNA expression ratio was also significantly up-regulated(
P
<
0.05). The protein expressions of cleaved-Caspase-9/Caspase-9 and Bax/Bcl-2 in RKO cells were increased by 95 μmol/L DHA(
P
<
0.01), while the protein expression levels of MMP-9, p-P38 MAPK, p-PI3K, p-Akt and Akt were decreased(P
<
0.01).
Conclusion
2
DHA has a good inhibitory effect on colorectal cancer,and its mechanism may be to trigger the endogenous apoptosis of RKO cells to prevent their proliferation and migration through inhibiting the MAPK/PI3K/Akt signaling pathway.
双氢青蒿素结直肠癌RKO细胞细胞凋亡MAPK/PI3K/Akt信号通路
dihydroartemisinincolorectal cancerRKO cellscell apoptosisMAPK/PI3K/Akt signaling pathway
YANG Q Q, HOU C, HUANG D, et al. miR-455-5p functions as a potential oncogene by targeting galectin-9 in colon cancer[J]. Oncol Lett, 2017, 13(3): 1958-1964.
LI Y, WU Y Y, XIA Q, et al. Platycodon grandiflorus enhances the effect of DDP against lung cancer by down regulating PI3K/Akt signaling pathway[J]. Biomed Pharmacother, 2019, 120: 109496.
HAN J M, SONG H Y, KIM K I, et al. Polysaccharides from Annona muricata leaves protect against cisplatin‑induced cytotoxicity in macrophages by alleviating mitochondrial dysfunction[J]. Mol Med Rep, 2023, 27(1): 16.
龙晓芝, 耿耘, 郭晴晴. 近年中药抗肿瘤有效成分及作用机制研究进展[J]. 中华中医药学刊, 2015, 33(4): 862-864.
LONG X Z, GENG Y, GUO Q Q, et al. Research Advance on Anti-tumor Activity Components and Mechanisms of Traditional Chinese Medicine in Recent Years[J]. Chinese Archives of Traditional Chinese Medicine, 2015, 33(4): 862-864.
TONG Y L, LIU Y T, ZHENG H M, et al. Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/β-catenin signaling[J]. Oncotarget, 2016, 7(21): 31413-31428.
YI Y C, LIANG R, CHEN X Y, et al. Dihydroartemisinin Suppresses the Tumorigenesis and Cycle Progression of Colorectal Cancer by Targeting CDK1/CCNB1/PLK1 Signaling[J]. Front Oncol, 2021, 11: 768879.
BAI B J, WU F, YING K K, et al. Therapeutic effects of dihydroartemisinin in multiple stages of colitis-associated colorectal cancer[J]. Theranostics, 2021, 11(13): 6225-6239.
WANG Y J, YANG Z R, ZHU W L, et al. Dihydroartemisinin inhibited stem cell-like properties and enhanced oxaliplatin sensitivity of colorectal cancer via AKT/mTOR signaling[J]. Drug Dev Res, 2023, 84(5): 988-998.
WANG X W, ZHENG Y Y, CHAI Z B, et al. Dihydroartemisinin synergistically enhances the cytotoxic effects of oxaliplatin in colon cancer by targeting the PHB2-RCHY1 mediated signaling pathway[J]. Mol carcinog, 2022, 62(3): 293-302.
YANG Y Y, YU Y B, WANG J H, et al. Silica nanoparticles induced intrinsic apoptosis in neuroblastoma SH-SY5Y cells via CytC/Apaf-1 pathway[J]. Environ Toxicol Pharmacol, 2017, 52: 161-169.
LU W N, ZHENG F P, LAI D W, et al. Xuezhikang () reduced renal cell apoptosis in streptozocin-induced diabetic rats through regulation of Bcl-2 family[J]. Chin J Integr Med, 2016, 22(8): 611-618.
CHEN T, LI M, ZHANG R W, et al. Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy[J]. J Cell Mol Med, 2009, 13(7): 1358-1370.
BAUD V, KARIN M. Is NF-κB a good target for cancer therapy? Hopes and pitfalls[J]. Nat Rev Drug Discov, 2009, 8(1): 33-40.
MCCUBREY J A, STEELMAN L S, CHAPPELL W H, et al. Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response[J]. Oncotarget, 2012, 3(9): 954-987.
ASATI V, MAHAPATRA K D, BHARTI K S. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives[J]. Eur J Med Chem, 2016, 109: 314-341.
HENNESSY T B, SMITH L D, RAM T P, et al. Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery[J]. Nat Rev Drug Discov, 2005, 4(12): 988-1004.
RANE M J, COXON P Y, POWELL D W, et al. p38 Kinase-dependent MAPKAPK-2 activation functions as 3-phosphoinositide-dependent kinase-2 for Akt in human neutrophils[J]. J Biol Chem, 2001, 276(5): 3517-23.
PORTA C, PAGLINO C, MOSCA A. Targeting PI3K/Akt/mTOR Signaling in Cancer[J]. Front Oncol, 2014, 4: 64.
HUANG W C, HUNG M C. Induction of Akt Activity by Chemotherapy Confers Acquired Resistance[J]. J Formos Med Assoc, 2009, 108(3): 180-194.
LIN W F, XIE J L, XU N J, et al. Glaucocalyxin A induces G2/M cell cycle arrest and apoptosis through the PI3K/Akt pathway in human bladder cancer cells[J]. Int J Biol Sci, 2018, 14(4): 418-426.
LI C L, QIN Y, ZHONG Y, et al. Fentanyl inhibits the progression of gastric cancer through the suppression of MMP-9 via the PI3K/Akt signaling pathway[J]. Ann Transl Med, 2020, 8(4): 118.
0
浏览量
0
下载量
0
CSCD
0
CNKI被引量
关联资源
相关文章
相关作者
相关机构